Background {#Sec1}
==========

Multidrug resistance (MDR) in bacteria is usually mediated by the expression of efflux pumps or porins involved in transport, by the expression of mutated genes coding for specific drug targets or specific enzymatic barriers. As a matter of fact, MDR remains a major obstacle hindering successful antibacerial chemotherapy (Alekshun and Levy [@CR1]; Davin-Regli et al. [@CR7]; Nikaido [@CR44]).

One way of tackling the emergence of MDR is to diversify the chemical structures of anti-microbial drugs to which resistance has developed in order to extend their lifespan (De Clercq [@CR8]; Poole [@CR50]; Jeu et al. [@CR17]). Alternatively, the compounds exhibiting modest to significant antibacterial activities against MDR phenotypes, could be used in combination with the efflux inhibitors, in order to improve on the accumulation of the drug in the cells for optimal activities (Kuete et al. [@CR29]). It is not surprising that in response to anti-microbial resistance, major pharmaceutical companies have concentrated their efforts on improving chemotherapeutic agents in established drug classes (Taylor et al. [@CR54]). However, with the portfolio of antimicrobials currently available, most of the lead structures of current drugs have already been explored. Today, large-scale empirical screening of synthetic, semi-synthetic and natural chemical entities in chemical libraries for anti-microbial activities is investigated (Kimberlin and Whitley [@CR23]). The compounds of interest for the development of novel drugs include those that target different proteins or biochemical processes compared to those in current use and those that inhibit bacterial efflux pumps (Kuete et al. [@CR29]). Natural products have been a particularly rich source of anti-infective agents, yielding, for example, the penicillins in 1940, the tetracyclines in 1948 and the glycopeptides in 1955 (Silver and Bostian [@CR53]). In the current study the antibacterial activities of compounds from several families (anthraquinones, naphthoquinones, benzoquinones, chalcones, flavones, flavanones, clerodane, and kaurane diterpenoids) were determined against different bacterial strains expressing MDR phenotypes. Furthermore, the chemical moieties relevant for pharmacophore binding were analyzed by their structure activity relationships (SAR) studies of related compounds.

Results and discussion {#Sec2}
======================

Studied compounds {#Sec3}
-----------------

The natural and modified compounds investigated in the current study were previously isolated from Kenyan plants (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). These included quinones; four anthraquinones namely; chrysophanol (**1**) (Fairbairn and El-Muhtadi [@CR13]; Midiwo and Rukunga [@CR37]; Zhang et al. [@CR61]), emodin (**2**) (Munavu et al. [@CR41]; Chang et al. [@CR3]), 3,6,8-trihydroxy-1-methylanthraquinone-2-carboxylic acid; Me ester (**3**) (Mehandale et al. [@CR34]; Dagne et al. [@CR6]), aloesaponol I; (-)-form (**4**) (Yagi et al. [@CR58]; Dagne et al. [@CR5]; Midiwo et al. [@CR40]), a naphthoquinones; 5-hydroxy-2-methyl-1,4-naphthalenedione, plumbagin (**5**) (Sidhu et al. [@CR52]; Yuan and Chao [@CR60]), thirteen related benzoquinones; 2,5-dihydroxy-3-ethyl-2,5-cyclohexadiene-1,4-dione (**6**) (Khurana et al. [@CR22]) and synthetic derivatives, 2,5-dihydroxy-3-propyl-2,5-cyclohexadiene-1,4-dione (**7**), 2,5-dihydroxy-3-butyl-2,5-cyclohexadiene-1,4-dione (**8**), 2,5-dihydroxy-3-heptyl-2,5-cyclohexadiene-1,4-dione (**9**), 2,5-dihydroxy-3-nonyl-2,5-cyclohexadiene-1,4-dione, homoembelin (**10**) (Murthy et al. [@CR42]), 2,5-dihydroxy-3-tridecyl-2,5-cyclohexadiene-1,4-dione, rapanone (**11**) (Wouters and Verhecken [@CR56]), 2,5-dihydroxy-3-pentadecyl-2,5-cyclohexadiene-1,4-dione (**12**) (Ogawa and Natori [@CR45], [@CR46]), 2-hydroxy-5-methoxy-3-undecyl-1,4-benzoquinone, 5-*O*-methylembelin (**13**) (Merian and Schlittler [@CR36]), 2,5-dimethoxy-3-undecyl-1,4-benzoquinone, 2,5-di-*O*-dimethylembelin (2,5-dimethoxy-3-undecyl-\[1,4\]-benzoquinone) (**14**) (Wu et al. [@CR57]), 2,5-dihydroxy-3-methyl-6-(14-nonadecenyl)-1,4-benzoquinone, maesaquinone (**15**) (Ogawa and Natori [@CR45], [@CR46]; Ogawa and Natori [@CR47]; Manguro et al. [@CR31]), 2,5 dimethoxy-6-(14-nonadecenyl)-1,4-benzoquinone (**16**), 1,2,4,5-tetraacetate-3-methyl-6-(14-nonadecenyl)-cyclohexadi-2,5-diene (**17**), ardisiaquinone (**18**) (Yoshihir et al. [@CR59]; Ogawa and Natori [@CR47]), flavonoids including six chalcones; 3′,5′-dihydroxy-1′-methoxychalcone (**19**), 1′,5′-dihydroxy-3′-methoxychalcone (**20**), 1′,3′-dihydroxy-2′,5′-dimethoxychalcone (**21**), 5′-hydroxy-1′,3′-dimethoxychalcone (**22**), 1′,3′,5′-trihydroxy-2′-methoxychalcone (**23**), 1,5-diacetate-3′-methoxychalcone (**24**) (Midiwo et al. [@CR38]; [@CR39]), ten polymethoxylated flavones and their semi-synthetic derivatives; 5,7-dihydroxy-3,4-dimethoxyflavone (**25**), 3,5,4′-trihydroxy-7 methoxyflavone (**26**), 5,7-dihydroxy-3,6,4′-trimethoxyflavone (**27**), 5,4′-dihydroxy-3,7-dimethoxyflavone (**28**), 5-hydroxy-3,7,4′-trimethoxyflavone (**29**) (Omosa et al. [@CR48]), 3,5,6,7,4′-pentamethoxyflavone (**30**), 5-hydroxy-2′,3′,4′,5′-tetramethoxyflavone (**31**), 5-hydroxy-7,2′,3′,4′,5′-pentamethoxyflavone (**32**) (Juma et al. [@CR19]), 5,7-diacetate-3,6,4′-trimethoxyflavone (**33**) semi-synthetic derivative of 5,7-dihydroxy-3,6,4′-trimethoxyflavone (Omosa et al. [@CR48]), 5,7-diacetate-3,4′-trimethoxyflavone (**34**) a semi-synthetic derivative of 5,7-dihydroxy-3,4′-trimethoxyflavone; three flavanones; 5,4′-dihydroxy-7-methoxyflavanone (**35**) (Kerubo et al. [@CR21]), 3,7-dihydroxy-5,8-dimethoxyflavanone (**36**), 5,7,4′-trihydroxy-3′-prenylflavanone (**37**) (Nakahara et al. [@CR43]); eleven diterpenoids, four clerodane type; dodonic acid (**38**), hautriwaic acid (**39**), 2β-hydroxyhardwickiic acid (**40**), hautriwaic acid lactone (**41**) (Omosa et al. [@CR48]), five trachylobane type; 6,17,19-trachylobanetriol; (ent-6α)-form (**42**) (Juma et al. [@CR20]), 2,6,19-trachylobanetriol; (ent-2α,6α)-form (**43**) (Midiwo et al. [@CR40]), 6,18,19-trachylobanetetrol; (ent-6α)-form (**44**), 2,18,19-trachylobanetriol; (ent-2α)-form (**45**), 2,6,18,19-trachylobanetetrol; (ent-2β,6α)-form (**46**) (Juma et al. [@CR20]) and two kaurane type; *ent*-kaur-16-en-2α,18,19-triol (**47**), *ent*-kaur-16-en-18,19-diol (**48**) (Midiwo et al. [@CR40]) Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}.Fig. 1Chemical structures of the compounds tested; **1**, chrysophanol; **2**, emodin; **3**, 3,6,8-trihydroxy-1-methylanthraquinone-2-carboxylic acid; Me; **4**, aloesaponol I; **5**, plumbagin; **6**, benzoquinones; 2,5-dihydroxy-3-ethyl-2,5-cyclohexadiene-1,4-dione; **7**, 2,5-dihydroxy-3-propyl-2,5-cyclohexadiene-1,4-dione; **8**, 2,5-dihydroxy-3-butyl-2,5-cyclohexadiene-1,4-dione; **9**, 2,5-dihydroxy-3-heptyl-2,5-cyclohexadiene-1,4-dione; **10,** homoembelin; **11**, rapanone; **12**, 2,5-dihydroxy-3-pentadecyl-2,5-cyclohexadiene-1,4-dione; **13**, 5-*O*-methylembelin; **14**, 2,5-di-*O*-dimethylembelin; **15**, maesaquinone; **16**, 2,5 dimethoxy-6-(14-nonadecenyl)-1,4-benzoquinone; **17**, 1,2,4,5-tetraacetate-3-methyl-6-(14-nonadecenyl)-cyclohexadi-2,5-diene; **18**, ardisiaquinone; **19**, 3′,5′-dihydroxy-1′-methoxychalcone; **20**, 1′,5′-dihydroxy-3′-methoxychalcone; **21**, 1′,3′-dihydroxy-2′,5′-dimethoxychalcone; **22**, 5′-hydroxy-1′,3′-dimethoxychalcone; **23**, 1′,3′,5′-trihydroxy-2′-methoxychalcone; **24**, 1,5-diacetate-3′-methoxychalconeFig. 2Chemical structures of the compounds tested; **25**, 5,7-dihydroxy-3,4-dimethoxyflavone; **26**, 3,5,4′-trihydroxy-7 methoxyflavone; **27**, 5,7-dihydroxy-3,6,4′-trimethoxyflavone; **28**, 5,4′-dihydroxy-3,7-dimethoxyflavone; **29,** 5-hydroxy-3,7,4′-trimethoxyflavone; **30**, 3,5,6,7,4′-pentamethoxyflavone; **31**, 5-hydroxy-2′,3′,4′,5′-tetramethoxyflavone; **32**, 5-hydroxy-7,2′,3′,4′,5′-pentamethoxyflavone; **33**, 5,7-diacetate-3,6,4′-trimethoxyflavone; **34**, 5,7-diacetate-3,4′-trimethoxyflavone; **35**, 5,4′-dihydroxy-7-methoxyflavanone; **36**, 3,7-dihydroxy-5,8-dimethoxyflavanone; **37**, 5,7,4′-trihydroxy-3′-prenylflavanone; **38**, dodonic acid; **39**, hautriwaic acid; **40**, 2β-hydroxyhardwickiic acid; **41**, hautriwaic acid lactone; **42**, 6,17,19-trachylobanetriol; (ent-6α)-form; **43**, 2,6,19-trachylobanetriol; (ent-2α,6α)-form; **44**, 6,18,19-trachylobanetetrol; (ent-6α)-form; **45**, 2,18,19-trachylobanetriol; (ent-2α)-form; **46**, 2,6,18,19-trachylobanetetrol; (ent-2β,6α)-form; **47**, *ent*-kaur-16-en-2α,18,19-triol; **48**, *ent*-kaur-16-en-18,19-diol

The compounds were tested for their ability to prevent the growth of MDR and reference strains of Gram-negative bacteria, alone and for some of the active compounds, in the presence of the efflux pump inhibitor (EPI), PAβN (Table [2](#Tab2){ref-type="table"}).

The antibacterial activity of compounds has been defined as significant when the MIC is below 10 µg/mL, moderate when 10 \< MIC \< 100 µg/mL and low when MIC \> 100 µg/mL (Kuete [@CR24]; Kuete and Efferth [@CR25]). Compound **1** was inactive against all drug sensitive and resistant bacteria. However, **2** with a similar skeletal structure as **1** except for the presence of an hydroxyl group at C6 was more active exhibiting antimicrobial activities against Gram-negative *E. coli* A102 and AG 100ATet; *K. pneumoniae* KP55, KP63, *E. aerogenes* EA289 with MIC values of 128, 16, 32, 128 and 128 µg/mL, respectively. This anthraquinone showed good activities against MRSA 4, 6 and 8 with MIC values of 4 (vs 8), 4 (vs 64), 4 (vs 32) μg/mL, respectively, more active than the standard drug, chloramphenicol. These results are comparable to those obtained by Hatano et al. ([@CR16]), where emodin exhibited noticeable antibacterial effects against four MRSA strains (OM481, OM505, OM584, OM623) and one MRSA strain (209P) with MIC values of about 64 μg/mL but less sensitive against the Gram-negative strains, *E. coli* K12 and *Pseudomonas aeruginosa* PA01 with MIC \> 128 μg/mL. The presence of an hydroxyl group in place of a methyl group at C3 or a methyl in place of hydroxyl group at C8 and an additional methyl ester (COOMe) group at C7 in **3** substantially reduced antimicrobial activities especially against the MRSA phenotype, as this compound did not inhibit these bacteria. However, this compound exhibited minimal antimicrobial activities against the standard *E. coli* ATCC8739 strain with MIC values of 256 µg/mL, which was not inhibited by **2**. Compound **4,** which is a derivative of **3** with a slightly different skeletal structure in ring A had antimicrobial activities similar to those of **3**, probably due to the total number of hydroxyl groups (3), methyl (1) and acetate irrespective of the positions of these substituents in the anthroquinone skeleton. Furthermore, the substitution pattern of ring C was similar in the two compounds. This compound was also inactive against all bacteria strains tested except for the reference *E. coli* ATCC8939 strain with a MIC value of 256 µg/mL.

The naphthoquinone, plumbagin (**5**) was active against both Gram-positive and Gram-negative bacteria tested with interesting MIC values ranging from 2 to 64 μg/mL. This naphthoquinone exhibited exceptionally good antimicrobial activities against MRSA 3, 4, 6, 8 compared to chloramphenicol with MIC values of 64 (vs \>256), 2 (vs 8), 2 (vs 64) and 2 (vs 32) µg/mL, respectively. The good antibacterial activity of this compound is consistent to data previously documented (Kuete et al. [@CR29]). Several studies have also demonstrated the potencies of plumbagin against bacteria and fungi (Brice [@CR2]; Durga et al. [@CR9]; Gujar [@CR15]) as well as cancer (Melo et al. [@CR35]). In a separate study the in vitro antimicrobial activities of plumbagin against selected microorganisms were reported to be significantly higher than the standard drug, streptomycin (Jeyachandran et al. [@CR18]). The antibacterial potencies of different related benzoquinones were established against both Gram-negative and Gram-positive bacteria strains. Compounds **6**--**8** with a 2--4 carbon alkyl side chain revealed similar activities against various microbes with MIC ranging from 16 to 256 µg/mL. There was a marked improvement of antibacterial activities with increasing length of the lipophilic chain to 7 as shown by **9** exhibiting low MIC values ranging from 4 to 32 µg/mL.

There was reduced antimicrobial activities with compounds **10** (C9) against most bacteria strains with the lowest activity recorded having MIC ≥ 256 µg/mL against *E. coli* ATCC 8739, AG102, AG100A~Tet~; *S. aureus* A4, A11; *K. pneumoniae* ATCC11296, KP63; *P. stuartii* ATCC29916, NAE16; *E. aerogenes* EA27 and against all strains of MRSA. The activities of compound **11 **(C13) against specific bacteria was comparable to that of **9** especially against the Gram-negative *E. coli* AG100A~Tet~, *K. pneumoniae* KP55, KP63 with MIC values ranging from 16 to 32 µg/mL.

This compound exhibited selective activities against specific Gram-negative bacteria such as *E. coli* AG100A~Tet~, *K. pneumoniae* KP55, KP63 and the Gram-positive MRSA 4, 6, 8 some of which were more potent than chloramphenicol (Table [2](#Tab2){ref-type="table"}).

Increasing chain lengths of the alkyl group from C15 in compound **12** to C19 in **15**--**17** had no effect on further improving the activities of compound **11** (C13) against most bacteria. However, **17** showed selective activities against three strains of MRSA including MRSA4, 6 and 8. Reduction of the two keto groups of **15** and subsequent acetylation at C1, 2, 4, 5 positions as seen in **17** improved the antibacterial activities against specific bacteria including MRSA 4, 6, 8. The MIC values of **17** against MRSA4 and 8 strains were observed to be almost as low as those of the standard drug with MIC values of 32 (vs 8) and 64 (vs 32), respectively (Table [2](#Tab2){ref-type="table"}) while that against MRSA6 was more active than the standard drug (16 (vs 64) µg/mL. This observation could imply that increasing the chain length up to C7 probably results in more profound antibacterial activities. Further increases in chain length had little effect on the improvement of the antibacterial activities but led to selectivity of the drugs towards specific bacteria, as seen in **11**--**13**. The alkyldibenzoquinone, ardisiaquinone B (**18**) with two benzoquinone rings at the end of the alkyl chain (C16) showed improved activities as compared to the monomeric benzoquinone with a similar number of carbon atoms in the lipophilic chain. This compound showed interesting activities against all strains of *E. coli*, *K. pneumoniae*, *P. staurtii* and MRSA. This compound was also potent against *P. aeruginosa* PA124 and *E. aerogenes* EA27 but seemed to be inactive against Gram-positive *S. aureus*.

Compound **19** with two hydroxyl groups, one at C3′and the other in *meta* orientation at C5′and one methoxy group also in *meta* orientation to the hydroxyl group at C3′, without a substituent at C2′ was active against two strains of MRSA 4 and 6. However, interchanging the hydroxyl group at C3′ for a methoxy group and vice versa completely reduced the antimicrobial activities against these two MRSA strains. This may imply that the substitution pattern of the substituents on ring B where at least one hydroxyl group is placed at C3′, an additional hydroxyl groups in *meta* orientation (either at C1′ and 5′), a methoxy group in *meta* orientation to the C3′ hydroxyl group (either at C1′ and 5′) as observed in **19** (hydroxyl at C3′, one *meta* position to have methoxy and the other hydroxyl) is important for minimal activities against the two strains of MRSA. Compound **21** with two methoxy groups and two hydroxyl groups in *meta* orientation was the most active compound of the evaluated chalcones; against the four MRSA strains. The increased antibacterial activities of this compound could be attributed to the additional oxygenation at C2′ position. The basic requirement for activities against MRSA strains (hydroxyl at C3′, one *meta* position to have methoxy and the other hydroxyl) was observed here too. However, more studies need to be undertaken to understand the active scaffold in the chalcone skeleton. Compound **22** with one hydroxyl group at C5′and two methoxy groups at C1′ and C3′ did not exhibit any antibacterial activities against all the strains of bacteria including MRSA most probably due to the lack of the required scaffold. Compound **23** with two hydroxyl group in *meta* position in ring A but was lacking a methoxy group in second *meta* position was inactive against all bacteria tested including the MRSA strains, except for the Gram-negative *E. aerogenes,* ATCC13048, with minimal activity.

Most of the flavones tested were polymethoxylated making them lipophilic and therefore showing minimal or no activities against the bacteria tested. Previous studies have shown that antifungal compounds tend to be more lipophilic compared to antibacterial compounds and hence these compounds should be tested for their antifungal potential (McClure [@CR33]; Omosa et al. [@CR49]). Compound **34** showed minimal activities against specific bacteria strains with MIC values ranging from 128 to 256 µg/mL most probably due to increase in hydrophilicity (Omosa et al. [@CR49]). The flavanones tested were also inactive due to their lipophilicity as shown in previous studies. The clerodanediterpenoids were inactive against all bacteria tested except for hautriwaic acid (Omosa et al. [@CR49]) which showed minimal activity against some bacterial strains. However, its lactone did not exhibit antimicrobial activities ≤256 µg/mL, most probably because of increased lipophilicity. The presence of a free hydroxyl group at C19 in the clerodane skeleton appears to be necessary for minimal activities against *S. aureus* SA 11, 12; *K. pneumoniae* KP55, 63; *P. aeroginosa* PA01 and *E. aerogenes* ATCC 13048 strains. The kaurane type diterpenoids exhibited similar antimicrobial profile as the clerodanes which could be attributed to their lipophilicity.

Role of efflux pumps in the susceptibility of tested bacteria {#Sec4}
-------------------------------------------------------------

In this study the compounds that attained certain threshold of activities including the anthraquinone, **2**; naphthaquinone, **5**; and some benzoquinones, **6**--**10**, **13** and **18** were combined with the efflux pump inhibitor, EPI, PAβN, in order to assess the involvement of efflux in the activities of these compounds. When tested alone compound **2** showed minimal antibacterial activities against some Gram-negative MDR strains including *E. coli* AG100 and 102, as well as *K. pneumoniae* KP 55 and K63 (Table [2](#Tab2){ref-type="table"}). However, there was substantial enhancement of activities of **2** with PAβN. The observed MICs without PAβN against *E. coli* AG102, 100A~Tet~; *K. pneumoniae* KP 55 and K63 were 128, 16, 32, 128 μg/mL. With PAβN the activities improved by \>4 fold, exhibiting MICs higher than the standard, chloramphenicol of 2, 4, \<2 and 2 μg/mL, respectively (Table [2](#Tab2){ref-type="table"}). This compound which exhibited good antibacterial activities against MDR Gram-positive bacteria alone also showed improved activities in combination with PAβN. However, the improvement was not as substantial as that observed against the Gram-negative bacteria. The naphthaquinone, plumbagin (**5**) which showed good activities even when tested alone exhibited minimal improvement with PAβN as compared to emodin (**2**) except against AG100A~Tet~ with \>8 fold increament. These results consistent with those obtained by Kuete et al. ([@CR29]). The antimicrobial activities against the Gram-positive MDR strains increased by \>4 fold against MRSA 6, 8 and \>2 fold for MRSA 4.

The benzoquinones, **6**--**10** and **18** showed enhancement in activity with PAβN most of which were \>2 and 4 folds, with **13** having MICs \< 10 μg/mL. These data clearly demonstrate that the quinones and chalcones tested are substrates of bacterial efflux pumps and should be combined to EPI in the fight against MDR bacterial infections. The obtained results are therefore consistent to data previously reported by Kuete et al. ([@CR29]), who highlighted the role of efflux pumps in the bacterial resistance to natural products.

Conclusion {#Sec5}
==========

In this study, various anthraquinones, naphthoquinones, benzoquinones, flavonoids (chalcones and polymethoxylated flavones) and diterpenoids (clerodanes and kauranes) were explored for their antimicrobial potential against different drug sensitive Gram-negative and Gram-positive bacteria.

The results show that the anthraquinone (**2**), naphthaquinone, plumbagin (**5**) benzoquinones (**11**, **12**, **17**, **18)**, chalcones (**19**, **21)** were active against MRSA bacteria strains with MIC value ranging from 2 to 128 µg/mL. Structure activity relationships of benzoquinones; which has not been carried out in previous studies, showed that antibacterial activities gradually increased with increasing side chain length from 2, 3, 4 for **6**, **7** and **8**, respectively, with optimal activities being realized with C7 (**9**). This study also showed that there is a minimum chain length that is required for maximum activity in the 2,5 dihydroxy-1,4-benzoquinone moieties. This studies showed that the minimum chain length required for optimal antimicrobial activities was C7 (compound **9**) beyond which no marked activity improvement has been observed. Some compounds selectively inhibited the growth of specific but not all bacteria. These studies revealed that the presence of a hydroxyl group at C3′ together with a methoxy group and a second hydroxyl group in meta orientation in ring B of the chalcone skeleton appears to be necessary for minimal activities against MRSA 4 and 6 as elaborated in **19**--**24**.

These data clearly demonstrate that the tested compounds are substrates of bacterial efflux pumps and should be combined to EPI in the fight against MDR bacterial infections. The obtained results are therefore consistent to data previously reported by Kuete et al. ([@CR29]), who highlighted the role of efflux pumps in bacterial resistance to natural products.

Methods {#Sec6}
=======

Reagents and compounds {#Sec7}
----------------------

The chemicals used in antimicrobial assays were chloramphenicol ≥98 % (Sigma-Aldrich, St-Quentin-Fallavier, France) as reference antibiotic and *p*-Iodonitrotetrazolium chloride ≥97 % (INT, Sigma-Aldrich) as microbial growth indicator (Eloff [@CR12]; Mativandlela et al. [@CR32]). Phenylalanine-Arginine-*β*-Naphthylamide (PAβN; Sigma-Aldrich) was used as efflux pumps inhibitor (EPI). Natural products (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}) used in the study were obtained from the chemical bank of the natural products research laboratory of the Chemistry Department, University of Nairobi, Kenya. Isolation and identification of the compounds in study were previously reported from the following plants; a number of *Rumex* species including; *Rumex dentatus, R. abyssinicus, R. usambarensis, R. bequaertii, R. ruwenzoriensis, R. crispus*; *Plumbago zeylanica,Myrsine africana*, *Maesa lanceolata*, *Rapanea melanphloes*, *Aloe saponaria*, *Erythrina abyssinica*, *Polygonum senegalense*, *Psiadia punctulata*, *Dodonaea angustifolia* and *Senecio roseiflorus*.

Bacterial strains and culture media {#Sec8}
-----------------------------------

MDR isolates and reference strains of *Escherichia coli*, *Enterobacter aerogenes*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* and *Staphylococcus aureus* are summarized in Table [1](#Tab1){ref-type="table"}. Isolates were conserved at 4 °C and were grown on Mueller--Hinton agar for 24 h before minimal inhibitory concentration (MIC) testing. Mueller--Hinton broth (MHB) was used for the susceptibility tests (Kuete et al. [@CR27]).Table 1Bacterial strains and featuresBacterial strainRelevant featuresReference*Escherichia coli*ATCC 8739 and ATCC 10536Reference strains AG100Wild-type *E. coli* K-12Viveiros et al. ([@CR55]) AG100ATetΔacrAB mutant of AG100; TET^R^ owing to acrF gene markedly overexpressedElkins and Mullis ([@CR11]) AG102AG100 over-expressing AcrAB pump*Enterobacter aerogenes*ATCC 13048Reference strainEA-CM64CHLR variant obtained fromGhisalberti et al. ([@CR14])EA3ATCC 13048 overexpressing AcrAB pumpPradel and Pagès ([@CR51])Clinical MDR isolate exhibiting energy-dependentNorfloxacin and chloramphenicol efflux with KAN^R^ AMP^R^NAL^R^ STR^R^ TET^R^EA27Clinical MDR isolate exhibitingEnergy-dependent NOR andCHL efflux; KAN^R^ AMP^R^ NAL^R^STR^R^ TET^R^EA289KAN-sensitive derivative of EA27EA294EA289 acrA::KAN^R^EA289EA289 tolC::KAN^R^*Klebsiella pneumoniae*ATCC 11296Reference strainKp55Clinical MDR isolate, TET^R^Chevalier et al. ([@CR4])Kp63AMP^R^ ATM^R^ CEF^R^Clinical MDR isolate, TET^R^ CHL^R^AMP^R^ ATM^R^*Pseudomonas aeruginosa*PA01Reference strainPA124MDR clinical isolateLorenzi et al. ([@CR30])*Staphyloccocus aureus*ATCC1026Reference strainSA3Clinical Laboratory isolate, sensitive to methicilinSA4SA11SA12Clinical laboratory isolate, MET^R^MRSA 3Dzoyem et al. ([@CR10])MRSA 4MRSA 6MRSA 8*KAN* kanamycin, *TET* tetracycline, *CHL* chloramphenicol, *NOR* norfloxacin, *AMP* ampicillin, *MET* methicillin, *NAL* nalidixic acid, *STR* streptomycin, *ATM* aztreonam, *CEF* cefalothin, *R* resistant, *MDR* multidrug-resistant

Determination of bacterial susceptibility {#Sec9}
-----------------------------------------
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